S-1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor-2

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 365-374

  Harada, Koji ^a   Supriatno, ^a   Kawashima, Yuichiro ^a   Yoshida, Hideo ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Fibroblast growth factor 2; Oral squamous cell carcinoma; Phosphorylated Akt; S 1; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FIBROBLAST GROWTH FACTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXONIC ACID; PROTEIN KINASE B; S 1 (COMBINATION); TEGAFUR; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL; ARTICLE; BIOSYNTHESIS; DRUG COMBINATION; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MOUSE; MOUTH TUMOR; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; OXONIC ACID; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TEGAFUR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34047256260     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Johnson NW: Epidemiology of oral cancer in risk markers of oral disease. In: Oral Cancer. N.W. Johnson (ed). Vol. 2. Cambridge University Press, pp3-26, 1991.
2. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T and Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl 547: 25-29, 2002. (Pubitemid 34913460)
3. Shingaki S, Takada M, Sasai K, Bibi R, Kobayashi T, Nomura T and Saito C: Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas. Am J Surg 185: 278-284, 2003. (Pubitemid 36298898)
4. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
5. Inuyama Y and Kida A: Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 28: 1381-1390, 2001.
6. Williams JK, Carlson GW, Cohen C, Derose PB, Hunter S, Jurkiewicz MJ, Lopez-Graniel CM, et al: Tumor angiogenesis as a prognostic factor in oral cavity carcinomas. J Exp Clin Cancer Res 20: 463-468, 2001.
7. Leung DW, Cachianes G, Kuang WH, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
8. Guo D, Jia Q, Song HY, Warren RS and Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270: 6729-6733, 1995.
9. Smith BD, Smith GL, Carter D, Sasaki CT and Haffty BG: Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18: 2046-2052, 2000.
10. Maeda T, Matsumura S, Hiranuma H, Jikko A, Furukawa S, Ishida T and Fuchihata H: Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status. J Clin Pathol 51: 771-775, 1998. (Pubitemid 28480335)
11. Gasparini G, Weider N, Maluta S, Pozza F, Boracchi P, Mezzetti M, Testolin A and Bevilacqus P: Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous cell carcinoma. Int J Cancer 55: 739-744, 1993.
12. Hegde P, Brenski AC, Caldarelli DD, Hutchinson J, Panje W, Wood NB, Leurgans S, et al: Tumor angiogenesis and p53 mutations: prognosis in head and neck cancer. Arch Otolaryngol Head Neck Surg 124: 80-85, 1998.
13. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K and Yamamoto E: Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 33: 369-374, 1997.
14. Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H and Herold-Mende C: Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 106: 34-44, 2003.
15. Li C, Shintani S, Terakado N, Klosek SK, Ishikawa T, Nakashiro K and Hamakawa H: Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas. Int J Oral Maxillofac Surg 34: 559-565, 2005.
16. Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381-395, 2002.
17. Wang G, Reed E and Li QQ: Apoptosis in prostate cancer: progressive and therapeutic implications (Review). Int J Mol Med 14: 23-34, 2004.
18. Perez-Tenorio G, and Stal O: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86: 540-545, 2002.
19. Huang S, Robinson JB, Deguzman A, Bucana CD and Fidler IJ: Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60: 5334-5339, 2000.
20. Yang LH, Wang KF, Zhou YP and Li ML: Role and mechanism of nuclear factor kappa B in angiogenesis of human ovarian carcinoma. Ai Zheng 23: 531-534, 2004.
21. Azuma M, Yamashita T, Aota K, Tamatani T and Sato M: 5-Fluorouracil suppression of NF-kappaB is mediated by the inhibition of IkappaB kinase activity in human salivary gland cancer cells. Biochem Biophys Res Commun 282: 292-296, 2001.
22. Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, Harada K, Kawaguchi S and Sato M: Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer 108: 912-921, 2004.
23. Schor AM, Schor SL and Allen TD: Effects of culture conditions on the proliferation, morphology and migration of bovine aortic endothelial cells. J Cell Sci 62: 267-285, 1983.
24. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated calorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987. (Pubitemid 17027905)
25. Pazouki S, Chisholm DM, Adi MM, Carmichael G, Farquharson M, Ogden GR, Schor SL and Schor AM: The association between tumour progression and vascularity in the oral mucosa. J Pathol 183: 39-43, 1997.
26. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M and Remacle J: Development of a sensitive multi-well colorimetric assay for active NF-kappaB. Nucleic Acids Res 29: E21, 2001.
27. Schoffski P: The modulated oral fluropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Dugs 15: 85-106, 2004.
28. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y and Sugita M: Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 93: 884-889, 2005.
29. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H and Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17: 4015-4023, 1997.
30. Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C and Van Waes C: Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 7: 435-442, 2001.
31. Burow ME, Weldon CB, Melnik LI, Duong BN, Collins-Burow BM, Beckman BS, and McLachlan JA: PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis. Biochem Biophys Res Commun 271: 342-345, 2000.
32. Motegi K, Azuma M, Aota K, Yamashita T, Tamatani T, Harada K, Yoshida H and Sato M: Effect of a mutant form of IkappaB-alpha on 5-fluorouracil-induced apoptosis in transformed human salivary gland cells. Oral Oncol 37: 185-192, 2001.
33. Harada K, Kawaguchi S, Supriatno, Kawashima Y, Yoshida H and Sato M: S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB. Cancer Lett 226: 161-168, 2005.
34. Yoneda K, Yamamoto T, Ueta E and Osaki T: Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett 133: 35-45, 1998.
35. Hirozane T, Matsumori A, Furukawa Y, et al. Prolongation of murine cardiac allograft survival with vesnarinone. J Mol Cell Cardiol 29: 67-76, 1997.
36. Tanaka S, Kawai K, Nakai S, Adachi M and Hori T: Apoptosis-inducing activity and growth suppression by vesnarinone on human glioma transplanted in nude mice. Neurol Res 21: 409-414, 1999.
37. Nara N, Kurokawa H, Tohda S, Tomiyama J, Nagata K and Tanikawa S: Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blasts in acute myelogenous leukemia. Exp Hematol 25: 199-204, 1997.